Nippon Shinyaku Co Ltd - Company Profile
Powered by 
All the data and insights you need on Nippon Shinyaku Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Nippon Shinyaku Co Ltd Strategy Report
- Understand Nippon Shinyaku Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Nippon Shinyaku Co Ltd (Nippon Shinyaku) develops, manufactures, and sells prescribed pharmaceuticals and functional foods. The company offers products for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. Nippon Shinyaku also provides functional food ingredients including health food ingredients, preservatives, spices and condiments, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.
Headquarters
Japan
Address
14, Nishinosho Monguchi-Cho, Kisshoin, Minami-Ku, Kyoto-Shi, 601-8550
Website
www.nippon-shinyaku.co.jp
Telephone
81 75 3211111
No of Employees
2,186
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4516 (TYO)
Revenue (2022)
$1.1B
4.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-8.7%
(2022 vs 2021)
Market Cap*
$2.0B
Net Profit Margin (2022)
XYZ
-12.9%
(2022 vs 2021)
* As of and is in US$
Nippon Shinyaku Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Categories: | Hypen |
| Gastrointestinal drugs | Lunabell LD |
| Cardiovascular drugs | Lunabell ULD |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into an agreement with MiNA Therapeutics to establish RNAa-based therapeutics focused on treating rare neurodegenerative conditions. |
| 2024 | Contracts/Agreements | In March, the company entered into an alliance agreement with Eli Lilly Japan K.K. to deliver pirtobrutinib. |
| 2024 | Contracts/Agreements | In February, the company and Vicore Pharma Holding AB entered into a partnership for the development and commercialization of Vicore's drug candidate C21 in Japan. |
Competitor Comparison
| Key Parameters | Nippon Shinyaku Co Ltd | Astellas Pharma Inc | Incyte Corp | Kyowa Kirin Co Ltd | Shionogi & Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | United States of America | Japan | Japan |
| City | Kyoto-Shi | Chuo-Ku | Wilmington | Chiyoda-Ku | Osaka-Shi |
| State/Province | Kyoto | Tokyo | Delaware | Tokyo | Osaka |
| No. of Employees | 2,186 | 14,484 | 2,524 | 5,974 | 5,680 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shigenobu Maekawa | Chairman | Executive Board | 2021 | 70 |
| Toru Nakai | President; Director | Executive Board | 2021 | 52 |
| Hitomi Kimura | General Manager - Resource Procurement, Production & Assurance Div.; Director | Executive Board | 2021 | 62 |
| Takanori Edamitsu | Director; General Manager-Business Management & Sustainability | Executive Board | 2022 | 60 |
| Kazuchika Takagaki | Director - Research and Development; Director | Executive Board | 2021 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward